Diarrhea – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Diarrhea – Pipeline Review, H2 2017’, provides an overview of the Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diarrhea

The report reviews pipeline therapeutics for Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diarrhea therapeutics and enlists all their major and minor projects

The report assesses Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diarrhea

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diarrhea

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A. Menarini Industrie Farmaceutiche Riunite Srl

Actelion Ltd

Aegis Therapeutics LLC

Akthelia Pharmaceuticals Ltd

Albireo Pharma Inc

Allergan Plc

Anatara Lifesciences Limited

Ardelyx Inc

Assembly Biosciences Inc

AzurRx BioPharma Inc

Bharat Biotech International Ltd

Cosmo Pharmaceuticals NV

DiscoveryBiomed Inc

GP Pharm SA

Miyarisan Pharmaceutical Company Ltd

Mucosis BV

Napo Pharmaceuticals Inc

Nippon Shinyaku Co Ltd

Novartis AG

Pfizer Inc

Prokarium Ltd

Rebiotix Inc

Recce Ltd

RedHill Biopharma Ltd

RxBio Inc

Scandinavian Biopharma Holding AB

Sigmoid Pharma Ltd

Summit Therapeutics Plc

Synthetic Biologics Inc

Syntiron LLC

Tasly Pharmaceutical Group Co Ltd

Wuhan Institute of Biological Products Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Diarrhea - Overview 7

Diarrhea - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Diarrhea - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Diarrhea - Companies Involved in Therapeutics Development 27

A. Menarini Industrie Farmaceutiche Riunite Srl 27

Actelion Ltd 27

Aegis Therapeutics LLC 28

Akthelia Pharmaceuticals Ltd 28

Albireo Pharma Inc 29

Allergan Plc 29

Anatara Lifesciences Limited 30

Ardelyx Inc 30

Assembly Biosciences Inc 31

AzurRx BioPharma Inc 31

Bharat Biotech International Ltd 32

Cosmo Pharmaceuticals NV 32

DiscoveryBiomed Inc 33

GP Pharm SA 33

Miyarisan Pharmaceutical Company Ltd 34

Mucosis BV 34

Napo Pharmaceuticals Inc 35

Nippon Shinyaku Co Ltd 35

Novartis AG 36

Pfizer Inc 36

Prokarium Ltd 37

Rebiotix Inc 37

Recce Ltd 38

RedHill Biopharma Ltd 38

RxBio Inc 39

Scandinavian Biopharma Holding AB 39

Sigmoid Pharma Ltd 40

Summit Therapeutics Plc 40

Synthetic Biologics Inc 41

Syntiron LLC 41

Tasly Pharmaceutical Group Co Ltd 42

Wuhan Institute of Biological Products Co Ltd 42

Diarrhea - Drug Profiles 43

ABIM-101 - Drug Profile 43

AKT-10081 - Drug Profile 44

ASP-7147 - Drug Profile 45

AZX-1101 - Drug Profile 46

Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 47

cadazolid - Drug Profile 48

Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile 50

CBM-588 - Drug Profile 52

cholestyramine - Drug Profile 54

crofelemer DR - Drug Profile 56

Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 60

Escherichia coli vaccine - Drug Profile 61

ETEC vaccine - Drug Profile 62

ETEC vaccine - Drug Profile 63

Etvax - Drug Profile 64

GXG-8 - Drug Profile 66

ibodutant - Drug Profile 67

IMSUTMR-1501 - Drug Profile 68

infectious diarrhea [serotype H11] vaccine - Drug Profile 69

LJN-452 - Drug Profile 70

octreotide acetate - Drug Profile 71

octreotide acetate MAR - Drug Profile 72

ondansetron hydrochloride CR - Drug Profile 73

ORP-101 - Drug Profile 80

Peptide to Activate NHE-3 for Diarrhea - Drug Profile 81

PF-06425090 - Drug Profile 82

prulifloxacin - Drug Profile 84

PZ-7475 - Drug Profile 86

RBX-2660 - Drug Profile 87

RDX-023 - Drug Profile 91

RDX-98940 - Drug Profile 92

RECCE-355 - Drug Profile 93

Recombinant Enzyme for Diarrhea - Drug Profile 94

ribaxamase - Drug Profile 95

ridinilazole - Drug Profile 101

rifamycin CR - Drug Profile 108

Rotavac-5C - Drug Profile 111

rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile 112

Rx-100 - Drug Profile 113

Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 115

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 116

Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile 117

SYN-006 - Drug Profile 118

SYN-007 - Drug Profile 119

thuricin CD - Drug Profile 120

Typhetec - Drug Profile 121

Vaccine 1 for Diarrhea - Drug Profile 122

Vaccine 2 for Diarrhea - Drug Profile 123

Vaccine for Traveler's Diarrhea - Drug Profile 124

Vaccine for Traveler's Diarrhea - Drug Profile 125

Yersinia pestis vaccine - Drug Profile 126

Diarrhea - Dormant Projects 127

Diarrhea - Discontinued Products 130

Diarrhea - Product Development Milestones 131

Featured News & Press Releases 131

Appendix 141

Methodology 141

Coverage 141

Secondary Research 141

Primary Research 141

Expert Panel Validation 141

Contact Us 141

Disclaimer 142

List of Tables

List of Tables

Number of Products under Development for Diarrhea, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Diarrhea – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2017

Diarrhea – Pipeline by Actelion Ltd, H2 2017

Diarrhea – Pipeline by Aegis Therapeutics LLC, H2 2017

Diarrhea – Pipeline by Akthelia Pharmaceuticals Ltd, H2 2017

Diarrhea – Pipeline by Albireo Pharma Inc, H2 2017

Diarrhea – Pipeline by Allergan Plc, H2 2017

Diarrhea – Pipeline by Anatara Lifesciences Limited, H2 2017

Diarrhea – Pipeline by Ardelyx Inc, H2 2017

Diarrhea – Pipeline by Assembly Biosciences Inc, H2 2017

Diarrhea – Pipeline by AzurRx BioPharma Inc, H2 2017

Diarrhea – Pipeline by Bharat Biotech International Ltd, H2 2017

Diarrhea – Pipeline by Cosmo Pharmaceuticals NV, H2 2017

Diarrhea – Pipeline by DiscoveryBiomed Inc, H2 2017

Diarrhea – Pipeline by GP Pharm SA, H2 2017

Diarrhea – Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017

Diarrhea – Pipeline by Mucosis BV, H2 2017

Diarrhea – Pipeline by Napo Pharmaceuticals Inc, H2 2017

Diarrhea – Pipeline by Nippon Shinyaku Co Ltd, H2 2017

Diarrhea – Pipeline by Novartis AG, H2 2017

Diarrhea – Pipeline by Pfizer Inc, H2 2017

Diarrhea – Pipeline by Prokarium Ltd, H2 2017

Diarrhea – Pipeline by Rebiotix Inc, H2 2017

Diarrhea – Pipeline by Recce Ltd, H2 2017

Diarrhea – Pipeline by RedHill Biopharma Ltd, H2 2017

Diarrhea – Pipeline by RxBio Inc, H2 2017

Diarrhea – Pipeline by Scandinavian Biopharma Holding AB, H2 2017

Diarrhea – Pipeline by Sigmoid Pharma Ltd, H2 2017

Diarrhea – Pipeline by Summit Therapeutics Plc, H2 2017

Diarrhea – Pipeline by Synthetic Biologics Inc, H2 2017

Diarrhea – Pipeline by Syntiron LLC, H2 2017

Diarrhea – Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017

Diarrhea – Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2017

Diarrhea – Dormant Projects, H2 2017

Diarrhea – Dormant Projects, H2 2017 (Contd..1), H2 2017

Diarrhea – Dormant Projects, H2 2017 (Contd..2), H2 2017

Diarrhea – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Diarrhea, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports